(redirected from Adempas)


(rye-oh-sig-ue-at ) ,


(trade name)


Therapeutic: pulmonary hypertension agents
Pharmacologic: soluble guanylate cyclase stimulators sgs
Pregnancy Category: X


Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH, WHO Group 4) after surgery or in non-surgical candidates.Treatment of pulmonary arterial hypertension (PAH, WHO Group 1)


Stimulates soluble guanyl cyclase (sGC) a cardiopulmonary enzyme and receptor for nitric oxide, which when stimulated produces cyclic guanine monophosphate, an important regulator of vascular tone, proliferation, fibrosis and inflammation. This pathway is dysregulated in pulmonary hypertension.

Therapeutic effects

Improved symptoms/exercise tolerance and delayed worsening.


Absorption: Well absorbed following oral administration (94%)
Distribution: Unknown.
Protein Binding: 95%
Metabolism and Excretion: Extensively metabolized (by CYP P1A1, CYP3A, CYP2C8, and CYP2J2); M1 metabolite is pharmacologically active; metabolites are excreted in urine and feces (great individual variation)
Half-life: 12 hr

Time/action profile (improvement in 6–min walk distance)

POwithin 2 wk8–16 wkunknown


Contraindicated in: Severe hepatic impairment (Child Pugh C)Severe renal impairment (CCr <15 mL/min or on dialysis)Known pulmonary veno-occlusive disease; Concurrent use of nitrates, nitric oxide donors or phosphodiesterase (PDE) inhibitors; Obstetric: May cause fetal harm, pregnancy should be avoided (negative pregnancy tests required before and monthly during treatment) Lactation: Discontinue breast feeding
Use Cautiously in: Resting hypotension, hypovolemia, severe left-ventricular outflow obstruction, autonomic dysfunction, concurrent antihypertensive therapy or CYP and p-gp/BCRP inhibitors (↑ risk of hypotension, consider dose reduction); Cigarette smokers (require ↑ doses, with subsequent adjustment if smoking is stopped)Patients with reproductive potential (effective contraception is required) Geriatric: Elderly may have ↑ blood levels and be more sensitive to drug effects; Pediatric: Safe and effective use in children has not been established.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness (most frequent)
  • headache (most frequent)


  • pulmonary edema (↑ in veno-occlusive disease)
  • hypotension (most frequent)


  • dyspepsia (most frequent)
  • gastritis (most frequent)
  • nausea (most frequent)
  • vomiting (most frequent)
  • constipation
  • diarrhea
  • gastroesopheal reflux
  • ↑ liver enzymes


  • bleeding (life-threatening)
  • anemia


Drug-Drug interaction

↑ risk of hypotension with concurrent use of nitrates, nitric oxide donors (including amyl nitrate ) or phosphodiesterase (PDE) inhibitors including specific PDE-5 inhibitors such as sildenafil, tadalafil or vardenafil and non-specific PDE inhibitors such as dipyridamole or theophylline, concurrent use is contraindicated Strong CYP and P-gp/BRCP inhibitors including azole antifungals (ketoconazole and itraconazole ) and protease inhibitors (ritonavir ) ↑ blood levels and the risk of adverse reactions including hypotension (consider ↓ initial dose).Strong CYP3A inducers including carbamazepine, phenobarbital, phenytoin and rifampin ↓ blood levels and may ↓ effectiveness.Concurrent use of antihypertensives including diuretics may ↑ risk of hypotension.Antacids ↓ absorption (separate doses by at least 1 hr)Cigarette smoking ↓ blood levels and effectiveness, ↑ dose may be necessary and dose re-adjustment required after smoking cessation.St. John's wort ↓ blood levels and may ↓ effectiveness.


Oral (Adults) 1 mg three times daily initially; if hypotension a risk factor, initiate treatment with 0.5 mg three times daily. Increase dose by 0.5 mg at 2 wk (or more) intervals up to maintenance dose of 2.5 mg three times daily; smokers— consider titrating to doses >2.5 mg three times daily if tolerated (re-adjust following smoking cessation); concurrent CYP and P-gp/BRCP inhibitors— consider initiating treatment at 0.5 mg three times daily, with careful monitoring for hypotension.


Tablets: 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg

Nursing implications

Nursing assessment

  • Monitor hemodynamic parameters and exercise tolerance prior to and every 2 wks during therapy.
  • Assess for signs and symptoms of pulmonary edema (shortness of breath). If confirmed, discontinue therapy.
  • Monitor patient for bleeding (hemoptysis, vagina, catheter site, hematemesis, intra-abdominal, cerebral) during therapy.
  • Lab Test Considerations: Obtain a negative pregnancy test prior to beginning, monthly during therapy, and 1 mo following treatment.
    • Monitor hepatic function periodically during therapy. May cause ↑ AST, ALT, and bilirubin. If clinically relevant ↑ of AST or ALT occur, or if ↑ are accompanied by ↑ bilirubin >2 x upper limit of normal, or by clinical symptoms of hepatotoxicity, discontinue therapy. May re­initiate therapy when hepatic enzyme levels normalize in patients who have not experienced clinical symptoms of hepatotoxicity.
    • Monitor CBC before starting and periodically during therapy. May cause anemia. Avoid therapy in patients with severe anemia.

Potential Nursing Diagnoses

Activity intolerance (Indications)


  • Only available through a restricted program, Adempas Risk Evaluation and Mitigation Strategy (REMS). Prescribers and pharmacies must be enrolled and certified. All female patients must enroll and comply with pregnancy testing and contraception requirements. Male patients do not need to enroll.
  • Oral: Administer 3 times daily. If patient at risk for hypotension, begin with 0.5 mg dose. If systolic BP >95 and patient is asymptomatic, may increase by 0.5 mg three times/day up to 2.5 mg three times daily. Do not increase sooner than every 2 wks. If symptoms of hypotension occur, decrease dose by 0.5 mg three times/day. If dose is missed more than 3 days, begin titration again.
    • Titrate patients who smoke to doses >2.5 mg three times/day, if tolerated. May need to decrease dose if patient stops smoking.
    • May be administered without regard to food.

Patient/Family Teaching

  • Instruct patient to take riociguat as directed. If dose is missed, omit and continue with next scheduled dose.
  • Advise patient to avoid taking antacids within 1 hr of riociguat.
  • Advise patient to notify health care professional if they smoke.
  • May cause dizziness. Caution patient to avoid driving and other activities requiring alertness until response to medication is known.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Caution female patients that riociguat may harm fetus. Instruct females to use effective contraception (intrauterine device IUD, contraceptive implants, tubal sterilization) or a combination of methods (hormone method with a barrier method or two barrier methods) during and for at least a mo following discontinuation of therapy. If a partner’s vasectomy is method of contraception, a hormone or barrier method must be used along with this method. Counsel patient on emergency contraception. May decrease sperm count in male patients. Advise female patient to notify health care professional immediately if pregnancy is suspected and avoid breastfeeding.

Evaluation/Desired Outcomes

  • Increased exercise tolerance.
References in periodicals archive ?
The companys five key growth products the anticoagulant Xarelto, the eye medicine Eylea, the cancer drugs Xofigo und Stivarga and the pulmonary hypertension treatment Adempas made a major contribution to this performance, generating sales of EUR 5.
Combined sales of key growth products Xarelto, Eylea, Stivarga, Xofigo and Adempas are expected to reach more than pound 6 billion globally, according to Bayer.
Sales of Bayer's pharmaceuticals segment climbed nearly 10 percent in 2015 driven by five recently launched products--Xarelto, Eylea, Stivarga, Xofigo and Adempas.
In October 2013, riociguat was approved in the US under the name Adempas for use in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgery and in PAH.
Newly launched drugs Xarelto, Eylea, Stivarga, Xofig and Adempas, posted combined sales of 2.
Merck also announced a worldwide clinical development collaboration with Bayer to market and develop its portfolio of soluble guanylate cyclase (sGC) modulators, including Bayer's Adempas (riociguat).
The two companies also agreed to collaborate on the development and marketing of some drugs in the cardiovascular diseases area, including Bayer's Adempas approved for the treatment of pulmonary arterial hypertension, with Merck to pay Bayer USD1bn for the collaboration, as well as make additional proceeds based on certain sales goals being met.
The oral anticoagulant Xarelto, the eye medicine Eylea, the cancer drugs Xofigo and Stivarga, and the pulmonary hypertension treatment Adempas posted total combined sales of EUR 1,445 million (Q1 2016: EUR 1,187 million).
that, the newly launched drugs Xarelto, Eylea, Adempas, Stivarga and
This collaboration includes Bayer's ADEMPAS (riociguat) for both pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), as well as the investigational compound vericiguat, plus opt-in rights for other early-stage sGC compounds.
New drug launches also contributed to the overall success of Bayer's Healthcare subgroup, specifically the anticoagulant Xarelto for stroke and thrombosis prophylaxis; Eylea for age-related macular degeneration and macular edema; Stivarga for advanced metastatic colorectal cancer; Xofigo for bone metastases in prostate cancer; and Adempas for pulmonary hypertension.
The company's five key growth products - the anticoagulant Xarelto, the eye medicine Eylea, the cancer drugs Xofigo und Stivarga and the pulmonary hypertension treatment Adempas - made a major contribution to this performance, generating sales of EUR 5.